COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia
Scientific title
A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Glioblastoma Multiforme 0 0
Condition category
Condition code
Cancer 0 0 0 0

Study type
Description of intervention(s) / exposure
Treatment: Devices - Voyager

Experimental: Investigational Voyager Therapy - Investigational treatment with Voyager Therapy

Treatment: Devices: Voyager
Non-invasive RFE therapy

Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Incidence and evaluation of any serious adverse events associated with the Nativis Voyager System
Timepoint [1] 0 0
6 months
Primary outcome [2] 0 0
Tumor Response - Tumor imaging response (RANO) at two months of therapy.
Timepoint [2] 0 0
2 months
Secondary outcome [1] 0 0
Overall survival at six months compared with historical response
Timepoint [1] 0 0
6 months
Secondary outcome [2] 0 0
Progression free survival
Timepoint [2] 0 0
6 months

Key inclusion criteria
1. Subject has histologically confirmed diagnosis of GBM.

2. Subject has failed or intolerant to radiotherapy.

3. Subjects has failed or intolerant to temozolomide therapy.

4. Subject has progressive disease with at least one measureable lesion on MRI or CT.

5. Subject is at least 18 years of age.

6. Subject has a KPS = 60.

7. Subject has adequate organ and marrow function.

8. Subject has provided signed informed consent.
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Subject has life expectancy less than eight weeks

2. Subject has received other investigational therapy within the last 28 days.

3. Subject has received surgery within the last two weeks or not fully from prior

4. Subject has a clinically significant electrolyte abnormality.

5. Subject has an active implantable (e.g., neurostimulator, pacemaker) or other
electromagnetic device.

6. Subject has a metal implant, including a stent, in the head or neck that is
incompatible with MRI.

7. Subject is known to be HIV positive.

8. Subject is pregnant, nursing or intends to become pregnant during the study period.

9. Subject is participating in other investigational research.

10. Subject has any condition that at the discretion of the investigator would preclude
participation in the study.

11. Subject is unable or unwilling to comply with the protocol-required follow-up

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
St. Vincent's Hospital Melbourne - Melbourne
Recruitment postcode(s) [1] 0 0
3065 - Melbourne

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Nativis, Inc.

Ethics approval
Ethics application status

Brief summary
This feasibility study will assess the effects of the Nativis Voyager therapy in patients
with recurrent GBM who have either failed standard of care or are intolerant to therapy. The
study will enroll and treat up to eleven subjects over six months. Safety and clinical
utility will be evaluated.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Donna Morgan Murray, PhD
Address 0 0
Nativis, Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications